Residency · Residency · Radiation Oncology
Whole Breast Irradiation After Breast-Conserving Surgery
Overview
Adjuvant whole breast irradiation (WBI) following breast-conserving surgery (BCS) is the established standard of care for patients with early-stage invasive breast cancer and ductal carcinoma in situ (DCIS). This approach significantly reduces the risk of ipsilateral breast tumor recurrence (IBTR) by approximately 50% compared to BCS alone. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis demonstrated a critical clinical benefit: for every four local recurrences prevented at 10 years, about one breast cancer death is avoided at 15 years. In recent years, hypofractionated radiation regimens, such as 40-42.5 Gy delivered in 15-16 fractions or 26 Gy in 5 fractions, have become preferred over the conventional fractionation schedule of 50 Gy in 25 fractions for most patients, due to equivalent tumor control and improved convenience.
Landmark Clinical Trials
The NSABP B-06 trial, conducted by Fisher et al. and updated at 20 years, enrolled 1,851 women with invasive breast cancer measuring 4 cm or less. Participants were randomized to undergo mastectomy, BCS alone, or BCS followed by WBI. The 20-year IBTR rate was 39.2% in the BCS alone group compared to 14.3% in the BCS plus WBI group. Importantly, no differences were observed in overall survival or distant disease-free survival among the groups, establishing breast conservation combined with radiation as equivalent to mastectomy in terms of survival outcomes.
The EORTC 10801 trial, designed similarly to NSABP B-06, confirmed these findings by demonstrating equivalent survival between BCS plus radiotherapy and mastectomy, with a significantly lower IBTR when radiotherapy was added after BCS.
The EBCTCG meta-analysis in 2011 pooled data from 10,801 women across 17 trials comparing BCS with or without WBI. This analysis showed that WBI reduced the 10-year recurrence risk from 35% to 19.3%, an absolute reduction of 15.7%. Moreover, breast cancer mortality at 15 years decreased from 25.2% to 21.4%, an absolute reduction of 3.8%. This study established the "4 to 1 rule," indicating that for every four recurrences prevented at 10 years, approximately one breast cancer death is prevented at 15 years.
The UK Standardisation of Breast Radiotherapy (START) trials further refined fractionation strategies. START A compared conventional fractionation (50 Gy in 25 fractions) to hypofractionated regimens of 41.6 Gy or 39 Gy in 13 fractions, while START B compared 50 Gy in 25 fractions to 40 Gy in 15 fractions over three weeks. Ten-year results demonstrated that hypofractionated regimens, particularly 40 Gy in 15 fractions, provided equivalent tumor control with comparable or improved late normal tissue effects. Consequently, the 40 Gy in 15 fractions schedule from START B has become the most widely adopted hypofractionated regimen worldwide.
The FAST-Forward trial, published in 2020, randomized 4,096 women to receive either 40 Gy in 15 fractions over three weeks or ultra-hypofractionated schedules of 27 Gy or 26 Gy in 5 fractions over one week. The primary endpoint was IBTR at 5 years. The trial showed that 26 Gy in 5 fractions was non-inferior to 40 Gy in 15 fractions, with IBTR rates of 1.4% versus 2.1%, respectively. Normal tissue effects were comparable between these regimens. As a result, 5-fraction WBI has become a standard option, especially favored for its convenience and accelerated adoption during and after the COVID-19 pandemic.
Fractionation Schemes
Conventional fractionation involves delivering 50 Gy in 25 fractions over five weeks, with each fraction being 2 Gy. This was historically the standard approach but has largely been supplanted by hypofractionated regimens due to similar efficacy and improved patient convenience. Conventional fractionation remains in use at some centers, particularly for patients receiving concurrent regional nodal irradiation, although hypofractionation is increasingly applied in this setting as well.
Moderate hypofractionation typically consists of 40 to 42.56 Gy delivered in 15 to 16 fractions over three weeks. The START B trial used 40 Gy in 15 fractions, while the Canadian trial used 42.56 Gy in 16 fractions. This approach is now the preferred standard for the majority of patients undergoing WBI. The American Society for Radiation Oncology (ASTRO) guidelines from 2018 recommend hypofractionation for all patients receiving whole breast irradiation, regardless of age, tumor stage, or chemotherapy use.
Ultra-hypofractionation delivers 26 Gy in 5 fractions over one week, as studied in the FAST-Forward trial. This regimen is gaining widespread adoption globally due to its convenience. Another ultra-hypofractionated regimen of 28.5 Gy in 5 fractions was evaluated in the FAST trial but was associated with higher normal tissue toxicity, making 26 Gy in 5 fractions the preferred ultra-hypofractionated schedule.
| Regimen | Total Dose / Fractions | Duration | Key Trial | 5–10 yr IBTR |
|---|---|---|---|---|
| Conventional | 50 Gy / 25 fx | 5 weeks | Historical standard | ~6–8% |
| Moderate hypofractionation | 42.56 Gy / 16 fx | 3.2 weeks | Canadian trial | ~6.2% (10 yr) |
| Moderate hypofractionation | 40 Gy / 15 fx | 3 weeks | START B | ~4.3% (10 yr) |
| Ultra-hypofractionation | 26 Gy / 5 fx | 1 week | FAST-Forward | ~1.4% (5 yr) |
Tumor Bed Boost
The tumor bed is the area at highest risk for local recurrence after BCS. Administering a boost dose to this region reduces IBTR by approximately 50% in addition to whole breast irradiation. The EORTC 22881-10882 boost trial demonstrated that a 16 Gy boost lowered the 20-year IBTR from 16.4% to 12%, an absolute benefit of 4.4%. The greatest absolute benefit was observed in patients younger than 40 years, with an approximate 10% absolute reduction in recurrence.
Boost delivery can be performed sequentially, typically administering 10 to 16 Gy in 4 to 8 fractions after completion of WBI. Alternatively, a simultaneous integrated boost (SIB) technique delivers a higher dose per fraction to the tumor bed concurrently with WBI, such as 48 Gy to the tumor bed and 40 Gy to the whole breast over 15 fractions. Techniques for boost delivery include electron boosts, photon mini-tangents, or advanced methods like intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Accurate tumor bed delineation relies on surgical clips, preoperative imaging, and visualization of the seroma on planning CT scans.
Certain patients may safely omit the boost, particularly those over 70 years old with hormone receptor-positive, node-negative, and margin-negative disease. In this group, the absolute benefit of the boost is low. Trials such as PRIME II and CALGB 9343 support the omission of all radiotherapy in selected elderly patients with favorable tumor biology.
Treatment Planning and Technique
Patients are typically positioned supine with the ipsilateral arm abducted on a breast board or wing board to optimize reproducibility and comfort. Prone positioning is an option for women with large breasts to reduce skin fold toxicity and minimize radiation dose to the lung and heart. Lateral decubitus positioning is rarely used.
Field design involves medial and lateral tangential fields that encompass the entire breast tissue. Field borders are generally set superiorly at the infraclavicular fold or about 2 cm below the humeral head, inferiorly 1 to 2 cm below the inframammary fold, medially at the midline, and laterally at the mid-axillary line. The field-in-field technique, a form of forward-planned IMRT, is employed to reduce dose hotspots to less than 107-110% of the prescription dose, improving dose homogeneity. Full IMRT or VMAT may be used for patients with complex anatomy, bilateral breast treatment, or when cardiac sparing requires optimization.
Critical organs at risk include the heart, especially for left-sided breast cancers, where the ideal mean heart dose is less than 4 Gy and less than 8 Gy is acceptable with deep inspiration breath hold (DIBH). The left anterior descending artery (LAD) dose should be minimized. The ipsilateral lung dose is typically constrained to a V20 (volume receiving 20 Gy) of less than 15-20%. Scatter dose to the contralateral breast should be minimized. When regional nodes are treated, the brachial plexus maximum dose should be kept below 66 Gy.
Omission of Radiation After BCS
The CALGB 9343 trial studied women aged 70 years or older with T1N0, estrogen receptor-positive tumors who were treated with tamoxifen. Patients were randomized to BCS plus tamoxifen alone or BCS plus tamoxifen and WBI. At 10 years, the IBTR was 10% in the tamoxifen-alone group compared to 2% in the group receiving radiation. There were no differences in overall survival, distant disease-free survival, or breast cancer-specific survival. These findings support the omission of radiation in selected elderly, low-risk patients.
Similarly, the PRIME II trial enrolled women aged 65 years or older with T1-T2 tumors (up to 3 cm), node-negative, estrogen receptor-positive disease, and margins of at least 1 mm, all receiving endocrine therapy. The 10-year IBTR was 9.8% without radiation versus 1.3% with WBI, with no difference in overall survival. This trial confirms that radiation omission is reasonable in highly selected elderly patients who accept a modestly increased risk of local recurrence.
<image>A timeline graphic showing the evolution of whole breast irradiation fractionation from the 1980s to the present. Starting with 50 Gy/25 fractions (5 weeks), progressing through the Canadian trial 42.56 Gy/16 fractions (2005), START B 40 Gy/15 fractions (2008, 2023 update), and FAST-Forward 26 Gy/5 fractions (2020). Each regimen is annotated with treatment duration, key trial name, and 5-10 year IBTR rates, showing comparable outcomes with progressively shorter treatment courses.</image>
<image>A cross-sectional axial CT image at the level of the mid-breast showing a tangential beam arrangement for whole breast irradiation. The medial and lateral tangent fields are outlined with beam's-eye-view projections. The 95% isodose line (green) covers the breast tissue. The heart (red contour) and ipsilateral lung (blue contour) are shown with dose wash demonstrating minimal dose to these structures. Annotations show field-in-field segments used to reduce hot spots in the anterior breast.</image>
<image>A forest plot from the EBCTCG meta-analysis showing the relative reduction in 10-year any first recurrence with whole breast irradiation across subgroups defined by age, grade, ER status, T-stage, and nodal status. The overall hazard ratio favors WBI with a consistent benefit across all subgroups. The "4 to 1 rule" is annotated: for every 4 recurrences prevented, approximately 1 breast cancer death is avoided at 15 years.</image>
Key Clinical Pearls
Hypofractionation has become the standard of care for whole breast irradiation, with regimens such as 40 Gy in 15 fractions (as established by the START B trial) or 26 Gy in 5 fractions (from the FAST-Forward trial) preferred over the traditional 50 Gy in 25 fractions for nearly all patients. The tumor bed boost offers the greatest absolute benefit in younger women under 40 years old, who have the highest risk of local recurrence. In contrast, older women with favorable tumor biology can often omit the boost safely. Radiation can be entirely omitted after BCS in selected women aged 65 to 70 years or older with T1N0, estrogen receptor-positive tumors who are receiving endocrine therapy, as supported by the CALGB 9343 and PRIME II trials, although this approach carries a higher risk of IBTR. The EBCTCG "4 to 1 rule" provides a valuable framework for patient counseling by linking prevention of local recurrence to a meaningful survival benefit, with the absolute magnitude depending on baseline recurrence risk. To minimize acute skin toxicity, especially in patients with large breasts, field-in-field techniques or IMRT should be employed to keep maximum dose hotspots within 107-110% of the prescribed dose.
References
- Fisher B et al. "Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer." N Engl J Med. 2002;347(16):1233-1241.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). "Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials." Lancet. 2011;378(9804):1707-1716.
- Haviland JS et al. "The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials." Lancet Oncol. 2013;14(11):1086-1094.
- Murray Brunt A et al. "Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial." Lancet. 2020;395(10237):1613-1626.
- Bartelink H et al. "Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial." Lancet Oncol. 2015;16(1):47-56.
